Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection
Kaitlyn Bader, Senior Editor
AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component.
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195